METAVIA INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
METAVIA INC. (MTVA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 214.12 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-08-06
- METAVIA INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-06-30 was 103.12K shares.
- METAVIA INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-03-31 was 111.00K shares.
- METAVIA INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-12-31 was -222.23K shares.
- METAVIA INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-09-30 was 75.57K shares.
- METAVIA INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 22.22K shares, a 103.50% increase from fiscal 2024.
- METAVIA INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 10.92K shares, a 93.70% decline from fiscal 2023.
- METAVIA INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 173.40K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 103.12K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 214.12K shares 10-Q · filed 2026-08-06 | -8.12K shares derived: sum of 3 quarters · filed 2026-08-06 | 67.45K shares derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | 111.00K shares 10-Q · filed 2026-05-14 | -111.23K shares derived: sum of 2 quarters · filed 2026-05-14 | -35.66K shares derived: sum of 3 quarters · filed 2026-05-14 | ||
| 2025-12-31 | -222.23K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -146.66K shares derived: sum of 2 quarters · filed 2026-03-26 | 22.22K shares 10-K · filed 2026-03-26 | ||
| 2025-09-30 | 75.57K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 244.45K shares 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 168.88K shares 10-Q · filed 2025-08-07 | ||||
| 2024-12-31 | -72.98K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -72.98K shares derived: sum of 2 quarters · filed 2026-03-26 | -42.67K shares derived: sum of 3 quarters · filed 2026-03-26 | 10.92K shares 10-K · filed 2026-03-26 | 120.13K shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 30.31K shares derived: sum of 2 quarters · filed 2024-11-07 | 83.90K shares 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | 30.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 83.90K shares 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | 53.59K shares 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | 173.40K shares 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |